AquaVance Clear Fluoride Treatment
The Belport Company Inc., DBA Gingi-Pak · Decision date Oct 27, 2026
What did the FDA decide?
The FDA recorded a substantially equivalent decision for K262775, AquaVance Clear Fluoride Treatment, submitted by The Belport Company Inc., DBA Gingi-Pak. The decision carries a date of 2026-10-27 and appears in the agency's list of 510(k) final decisions. The device is classified under product code LBH within the dental specialty. Substantial equivalence in the 510(k) pathway indicates clearance to market, not approval of a premarket approval application.
The source record identifies the device by name and applicant only. It does not describe the device's components, formulation, intended use, or the predicate device it was compared against, and no summary or statement is included. Whether this submission represents an original clearance or a change to a previously cleared device is not stated. Those details would need to be confirmed in the underlying FDA decision documents rather than inferred from the listing.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Dental
- Decision date
- Oct 27, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262775
- Regulatory pathway
- 510(k) premarket notification
- Product code
- LBH
- Decision code
- SESE
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Varnish, Cavity.
- Product code
- LBH
- FDA device class
- 2
FDA decision timeline
K262775 received
Application receipt date recorded by FDA.
K262775 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code LBH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Profisil FreeK262243 | Kettenbach GmbH & Co. KG | 510(k) clearance | Sep 3, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
The Belport Company Inc., DBA Gingi-Pak
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Camarillo, CA
Sources and methodology
- Original FDA record: K262775
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records